Jieer Ying

8.1k total citations · 3 hit papers
95 papers, 1.7k citations indexed

About

Jieer Ying is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jieer Ying has authored 95 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 37 papers in Pulmonary and Respiratory Medicine and 25 papers in Molecular Biology. Recurrent topics in Jieer Ying's work include Gastric Cancer Management and Outcomes (25 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Jieer Ying is often cited by papers focused on Gastric Cancer Management and Outcomes (25 papers), Pancreatic and Hepatic Oncology Research (16 papers) and Colorectal Cancer Treatments and Studies (14 papers). Jieer Ying collaborates with scholars based in China, United States and South Korea. Jieer Ying's co-authors include Li Zhu, Bixia Liu, Haijun Zhong, Qi Xu, Cong Luo, Qi Xu, Juxiang Xiao, Yuxian Bai, Qing Wei and Weijia Fang and has published in prestigious journals such as Angewandte Chemie International Edition, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jieer Ying

90 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatogastroenterology

2012 513 citations Jieer Ying et al. profile →
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

2022 127 citations Shukui Qin, Zhendong Chen et al. Journal of Clinical Oncology profile →
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors

2024 87 citations Qing Wei, Can Hu et al. profile →

Peers

Jieer Ying

ONCOL

PRM

SURGE

HEPAT

Naoki Muguruma Japan

Adriana Romiti Italy

Volker Ellenrieder Germany

Chia‐Jui Yen Taiwan

Kazuo Hatsuse Japan

Masahiro Ohira Japan

Kazuhiro Koikawa Japan

Hirochika Toyama Japan

Hiroto Kinoshita Japan

Vlad Herlea Romania

Naoki Muguruma Japan

Jieer Ying

544 ×0.6

ONCOL

687 ×1.3

PRM

635 ×1.5

SURGE

168 ×0.5

HEPAT

469 ×1.4

Citations per year, relative to Jieer Ying Jieer Ying (= 1×) peers Naoki Muguruma

Countries citing papers authored by Jieer Ying

Since Specialization

Citations

This map shows the geographic impact of Jieer Ying's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jieer Ying with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jieer Ying more than expected).

Fields of papers citing papers by Jieer Ying

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jieer Ying. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jieer Ying. The network helps show where Jieer Ying may publish in the future.

Co-authorship network of co-authors of Jieer Ying

This figure shows the co-authorship network connecting the top 25 collaborators of Jieer Ying. A scholar is included among the top collaborators of Jieer Ying based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jieer Ying. Jieer Ying is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wei, Qing, Xiaoqing Xu, Jing‐Jing Li, et al.. (2024). Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study. The Oncologist. 29(4). 364–e578. 1 indexed citations

Ni, Jiaojiao, et al.. (2024). Potential mechanisms and targeting strategies of the gut microbiota in antitumor immunity and immunotherapy. Immunity Inflammation and Disease. 12(7). e1263–e1263. 3 indexed citations

Ying, Jieer, Qi Xu, Jing‐Jing Li, et al.. (2024). The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.. Journal of Clinical Oncology. 42(16_suppl). 4095–4095. 1 indexed citations

Guan, Xiaoqing, et al.. (2024). XYA-2: a marine-derived compound targeting apoptosis and multiple signaling pathways in pancreatic cancer. PeerJ. 12. e16805–e16805. 2 indexed citations

Zhao, Jing, Yubo Ma, Li‐Bin Pan, et al.. (2023). Chebulagic acid suppresses gastric cancer by inhibiting the AURKA/β-catenin/Wnt pathway. Frontiers in Pharmacology. 14. 1143427–1143427. 6 indexed citations

Chen, Muhua, et al.. (2023). Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes. SHILAP Revista de lepidopterología. 4(6). 1310–1327. 1 indexed citations

Wei, Qing, Yuchao Zhang, Can Hu, et al.. (2023). Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration. Clinical Cancer Research. 30(5). 984–997. 15 indexed citations

Lee, Kyung-Woo, Minkyu Jung, Jieer Ying, et al.. (2023). 1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study. Annals of Oncology. 34. S855–S856. 6 indexed citations

Wasan, Harpreet, James J. Harding, Jia Fan, et al.. (2023). 101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 study. Annals of Oncology. 34. S219–S219. 1 indexed citations

10.

Qin, Shukui, Zhendong Chen, Weijia Fang, et al.. (2022). Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 41(7). 1434–1443. 127 indexed citations breakdown →

11.

Zhang, Xiaoling & Jieer Ying. (2022). Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug. Current Oncology. 29(11). 8235–8243. 4 indexed citations

12.

Fu, Xianhua, Jieer Ying, Yang Liu, et al.. (2022). Dual targeted therapy with pyrotinib and trastuzumab forHER2‐positive advanced colorectal cancer: A phase 2 trial. Cancer Science. 114(3). 1067–1074. 20 indexed citations

13.

Peng, Zhi, Jia Wei, Wang Feng, et al.. (2021). Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. Clinical Cancer Research. 27(11). 3069–3078. 75 indexed citations

14.

Cheng, Xiangdong, Dan Wu, Nong Xu, et al.. (2021). Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC Cancer. 21(1). 56–56. 8 indexed citations

15.

Cheng, Yuan, Shukui Qin, Jin Li, et al.. (2021). A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX). Journal of Cancer Research and Clinical Oncology. 148(3). 673–684. 5 indexed citations

16.

Yu, Hang, et al.. (2020). FANCF hypomethylation is associated with colorectal cancer in Han Chinese. The Turkish Journal of Gastroenterology. 31(8). 558–565. 1 indexed citations

17.

Ding, Kefeng, Jingyu Chen, Jieer Ying, et al.. (2020). 469P Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial). Annals of Oncology. 31. S440–S440. 1 indexed citations

18.

Wei, Qing, et al.. (2020). <p>Correlation Between Hemoglobin Levels and the Prognosis of First-Line Chemotherapy in Patients with Advanced Gastric Cancer</p>. Cancer Management and Research. Volume 12. 7009–7019. 12 indexed citations

19.

Zhou, Cong, Bin Li, Tianyi Huang, et al.. (2019). GPX3 Hypermethylation in Gastric Cancer and its Prognostic Value in Patients Aged Over 60. Future Oncology. 15(11). 1279–1289. 21 indexed citations

20.

Luo, Cong, et al.. (2017). Case report of a <em>KIT</em>-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy. OncoTargets and Therapy. Volume 10. 4553–4557. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact